Skip to main navigation Skip to search Skip to main content

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial

  • Alexander M.M. Eggermont
  • , Vanna Chiarion-Sileni
  • , Jean Jacques Grob
  • , Reinhard Dummer
  • , Jedd D. Wolchok
  • , Henrik Schmidt
  • , Omid Hamid
  • , Caroline Robert
  • , Paolo A. Ascierto
  • , Jon M. Richards
  • , Céleste Lebbé
  • , Virginia Ferraresi
  • , Michael Smylie
  • , Jeffrey S. Weber
  • , Michele Maio
  • , Cyril Konto
  • , Axel Hoos
  • , Veerle de Pril
  • , Ravichandra Karra Gurunath
  • , Gaetan de Schaetzen
    • Stefan Suciu, Alessandro Testori

Research output: Contribution to journal › Article › peer-review

1152 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science